Spritam Shortage: What Providers and Prescribers Need to Know in 2026

If your patients are calling the office to report difficulty filling their Spritam (levetiracetam) prescriptions, they are not imagining things. Spritam — the world's first FDA-approved 3D-printed drug — occupies a unique position in the pharmaceutical landscape: a specialty medication with genuine clinical advantages for select patients, but a distribution footprint that doesn't match mainstream retail pharmacy networks. This briefing covers what prescribers need to know about Spritam's current availability, what's driving the access challenges, and concrete steps you can take to support your patients.

Current Availability Status (2026)

Spritam is not on the FDA's official drug shortage database as of 2026. Aprecia Pharmaceuticals continues to manufacture all four dose strengths (250 mg, 500 mg, 750 mg, 1000 mg), and an authorized generic (Levetiracetam Tablets for Oral Suspension, distributed by Prasco Laboratories) is the identical product from the same manufacturing facility.

However, the operational reality for patients does not match this clean "not in shortage" designation. Spritam has a narrow retail distribution footprint. Many high-volume chain pharmacies (CVS, Walgreens, Rite Aid) do not routinely stock it. Patients in rural areas and smaller metro markets face the greatest access challenges. Specialty pharmacies, hospital-based outpatient pharmacies, and specific mail-order channels are the most reliable sources.

What Makes Spritam Uniquely Difficult to Distribute?

Understanding the structural factors helps prescribers set realistic expectations with patients and anticipate likely refill challenges:

Single-source specialized manufacturing. Aprecia's ZipDose® binder jetting process is categorically different from conventional tablet compression. A conventional tablet press can produce hundreds of thousands of tablets per hour; the layer-by-layer 3D printing process operates at a fundamentally different scale. This constrains total production volume relative to mainstream generic medications.

Wholesaler distribution patterns. Not all pharmacy wholesaler agreements include Spritam. Pharmacies that primarily source through McKesson, AmerisourceBergen, or Cardinal Health may have different Spritam access depending on their specific contract tiers. A pharmacy in your local network may be simply unable to order it through their normal supply chain.

Low formulary priority at chain pharmacies. Spritam has a relatively small prescriber base — primarily neurologists and epilepsy specialists serving patients with specific swallowing or compliance needs. Chain pharmacies optimize inventory for high-volume drugs. Spritam's prescription volume per location is typically insufficient to justify routine stocking.

Insurance routing to specialty pharmacy. Some commercial payers route Spritam to specialty pharmacy networks (step therapy or specialty tier placement), which many patients don't anticipate when filling what they expect to be a standard retail prescription.

Prescribing Best Practices to Improve Patient Access

Several prescribing and workflow changes can materially improve your patients' ability to fill Spritam:

ePrescribe with NDC number + DAW. Spritam's manufacturer explicitly recommends ePrescribing using the specific NDC (43485-101-60 for 250 mg; 43485-102-60 for 500 mg, etc.) and selecting Dispense as Written. This prevents automatic substitution with standard levetiracetam tablets, which are NOT the same 3D-printed formulation.

Direct patients to specialty and mail-order pharmacies at time of prescribing. Set expectations upfront: inform patients at the time of the first Spritam prescription that it may not be available at their usual pharmacy and that specialty or mail-order channels are likely required. Provide your office's recommended pharmacy list.

Prescribe 90-day supplies where appropriate. Once a reliable pharmacy source is identified, prescribing 90-day supplies through a mail-order channel reduces the frequency with which patients need to navigate the refill search. Many mail-order pharmacy programs provide cost savings on 90-day supplies as well.

Maintain a stock of samples. Spritam samples can be requested through the prescriber portal at spritamhcp.com. Having samples on hand allows you to bridge patients for a few days while they locate a pharmacy, preventing dangerous gaps in therapy.

Pre-authorize with payers. If your patient has commercial insurance, consider initiating prior authorization proactively at the time of prescribing rather than waiting for a pharmacy rejection. Document the clinical rationale (dysphagia, swallowing difficulty, tube feeding, pediatric patient unable to swallow tablets) in the PA.

Recommended Pharmacy Channels for Spritam

The following channels have the most reliable Spritam access and are worth building into your practice's standard referral workflow:

Blink Health / Blink Pharmacy Plus — Official savings program partner; specialty pharmacy with home delivery and PA support. Call 844-SPRITAM (844-777-4826).

HealthWarehouse.com — Linked from the official Spritam website; carries Spritam at cash price for patients with a valid prescription.

Hospital-affiliated outpatient pharmacies — Academic medical centers and large health systems often carry a broader formulary including specialty AEDs.

Independent pharmacies — Can special-order Spritam for established patients with 24–48 hours lead time.

When to Consider Therapeutic Alternatives

For patients who genuinely cannot access Spritam despite exhausting available channels, consider whether the clinical rationale for Spritam can be addressed another way:

Patients with dysphagia: Levetiracetam oral solution (100 mg/mL) is widely available as a generic and provides the same drug in liquid form, suitable for patients who cannot swallow tablets of any kind.

Patients without swallowing limitations: Standard levetiracetam IR tablets (generic Keppra) are bioequivalent, widely available, and far less expensive. For patients who were prescribed Spritam for convenience rather than medical necessity, a switch to generic levetiracetam IR is typically appropriate.

Patients requiring a different mechanism: Brivaracetam (Briviact) shares the SV2A mechanism with higher receptor affinity and may have a lower behavioral side effect burden. Lacosamide (Vimpat) offers a complementary sodium channel mechanism. Both are available in multiple formulations.

Patient Safety Reminder: Never Abruptly Discontinue

Counsel all Spritam patients — at every visit and every refill — that they should never discontinue levetiracetam abruptly. Sudden withdrawal significantly increases seizure risk, including potentially dangerous seizure clusters or status epilepticus. Patients should contact your office if they anticipate a supply gap of even 1–2 days. Your office should have a triage protocol for urgent AED access issues.

For a practical guide to helping patients locate Spritam at pharmacies near them, see: How to Help Your Patients Find Spritam in Stock. You can also refer patients directly to medfinder for Providers — a tool that calls pharmacies to check current Spritam stock so your patients don't have to.